The 2026 State of Lab Revenue Report breaks down the PAMA cuts, molecular billing risk, and denial trends hitting labs right now, plus the benchmarks the top-performing labs are hitting instead.
Free download. No commitment. Built for lab directors, billing managers, and RCM leaders.
Built from ADS laboratory client data and published industry sources, including CMS, ACLA, and CAP TODAY.
We'll never sell your information. Unsubscribe anytime.
Lab directors, billing managers, and RCM leaders evaluating 2026 revenue performance.
A four-chapter report covering PAMA risk, denial benchmarks, and molecular billing exposure. Free, no commitment.
About 10 minutes. Built to be skimmed by a billing team, not just read once and filed away.
Average denial rate for in-house lab billing teams in 2026
Denial rate labs see once they move to specialized lab RCM
Facing up to a 15% Medicare cut under 2026 PAMA rules
It isn't one problem. It's a regulatory shift and an operational one hitting labs at the same time.
No fluff. Just the data, the risk, and what it means for your lab's bottom line.
What the reporting window means for your reimbursement rates, and what to fix before it closes.
Why clean science still gets denied, and where documentation gaps are costing labs the most.
Real denial rate, A/R, and cost-to-collect data by billing model, specialty, and lab size.
How payers automate denials faster than most labs can appeal them, and how to close the gap.
MedicsRCM combines lab billing specialists with AI-driven denial management. If the numbers in this report look familiar, here's a quick look at what closing that gap involves.
See How MedicsRCM Works →Real-time denial analysis and payment likelihood scoring on every claim.
Bulk appeal submission by carrier, documentation merged and routed automatically.
Your billing protocols encoded and enforced automatically, every carrier, every code.
LIS/LIMS-agnostic billing and revenue cycle management built for laboratories.
"Our test menu and payer mix haven't changed. What changed is our workflow. We're now collecting more than 8% more on the exact same charges, and our cash flow has improved significantly as a result."CJ Driscoll, CFO, Precision Diagnostics (national toxicology & drug-testing lab)
Years in Business
EDI Transactions Handled
Compatibility with Virtually Any LIS
Sources. Denial rate, A/R, and staffing figures cited in this report and on this page are drawn from ADS laboratory client data and published 2026 industry sources, including CMS PAMA guidance, the American Clinical Laboratory Association, and CAP TODAY.
General. Figures cited are industry benchmarks compiled from the sources above and are not a guarantee of results for any individual laboratory. Individual results vary by specialty, payer mix, claim volume, and billing practices. This report is provided for informational purposes and does not constitute financial, legal, or compliance advice.